Promising Therapy for a Lethal Tick-Borne Viral Infection

Read our paper in Cell describing our work on the discovery and development of a a monoclonal antibody-based therapy against Crimean-Congo hemorrhagic fever virus (CCHFV), a highly virulent tick-borne pathogen affecting eastern and southern Europe, Africa, the Middle East, India, and Central Asia.

This work was the product of our NIH-funded international consortium, Prometheus, whose goal is to to develop antibody-based therapies against CCHFV and three other highly lethal viruses for which there are no approved vaccines or treatments.

Co-led by Max Fels in the lab (Team).

Learn more about the implications of our findings here.

See this New York Times story for more on Prometheus and watch a video about the Prometheus team.